HLX-301 are capable of binding to TIGIT and PD-L1, bringing CD8+ T cells to the tumor cells, which lead to an enhanced activation of CD8+ T cells by the increased interaction between HLA-I on the tumor cells and TCRs on T cells. Here, TIGIT is linked to neoplasm.